Treatment With Local PPARgamma Ligand in Distal Ulcerative Colitis

Herlev Hospital20 enrolled

Overview

Treatment with PPARgamma ligands have been shown to reduces intestinal inflammation in murine models of colitis. The aim of this study was to evaluate the effect of treatment with local PPARgamma ligand (rosiglitazone) in distal ulcerative colitis.The patients are treated with rosiglitazone enema, once a day, for fourteen days. Disease activity was assessed before and after treatment by endoscopical and clinical activity score.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Ulcerative Colitis

Interventions

RosiglitazoneDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Distal ulcerative colitis (Mayo Clinical Score \> 7) * Age \> 18 years * Written consent Exclusion Criteria: * Age \< 18 years * Severe ulcerative colitis * Systemic treatment with steroids or azathioprin within the last 3 month * Known liver or kidney disease * Severe heart failure * Pregnancy or breast feeding

Locations (1)

Dept. Gastroenterology C, Herlev University Hospital

Herlev, Denmark

RECRUITING

Outcomes

Primary Outcomes

Clinical response

Secondary Outcomes

Endoscopic response

Central Contacts

Gitte Pedersen

CONTACT

+ 45 44883418 gitped01@herlevhosp.kbhamt.dk

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.